(Q56837776)

English

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir

scientific article published on November 1, 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir (English)

0 references

0 references

infectious disease

0 references

anti-HIV agents

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872707

21 July 2024

Dominique Costagliola

object named as

Dominique Costagliola

10

0 references

Christine Rouzioux

9

object named as

Christine Rouzioux

0 references

Pierre-Marie Girard

8

object named as

Pierre-Marie Girard

0 references

author name string

Christophe Piketty

1

0 references

Laurence Weiss

2

0 references

Lambert Assoumou

3

0 references

Marianne Burgard

4

0 references

Aurélie Mélard

5

0 references

Jean-Michel Ragnaud

6

0 references

Michele Bentata

7

0 references

ANRS 116 SALTO Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872707

21 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20872707

21 July 2024

publication date

17 September 2010

0 references

November 2010

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20872707

21 July 2024

full work available at URL

https://hal.archives-ouvertes.fr/hal-00577327/file/PEER_stage2_10.1002%252Fjmv.21907.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872707

21 July 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjmv.21907

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.21907

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Journal of Medical Virology

0 references

82

0 references

11

0 references

1819-1828

0 references

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21907

21 January 2018

Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21907

21 January 2018

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

1

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART

2

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction

3

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

5

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial

6

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

CD4+ count-guided interruption of antiretroviral treatment

7

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection

8

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Biphasic decline of CD4 cell count during scheduled treatment interruptions

9

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy

10

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Prolonged treatment interruption in chronic HIV infection: a new strategy?

11

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients

12

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).

13

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

14

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

15

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

16

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

17

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial

18

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997.

19

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

20

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

21

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial

22

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences

24

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

AIDS across Europe, 1994-98: the EuroSIDA study

25

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy

29

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

30

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

31

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.

33

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count

34

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Immunological changes during treatment interruptions

36

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.

37

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

38

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment

39

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL

40

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

41

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Endothelial function in HIV-infected persons.

42

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence

43

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy

44

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies

45

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk

46

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l

47

1 reference

10.1002/JMV.21907

https://api.crossref.org/works/10.1002/JMV.21907

21 July 2024

Identifiers

10.1002/JMV.21907

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56837776&oldid=2209137965"